Combined modality therapy for rectal cancer

Cancer Journal

Volumn 16, Issue 3, 2010, Pages 253-261

  Minsky, Bruce D ^a,d   Röedel, Claus ^b   Valentini, Vincenzo ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ABDOMINAL PAIN; ABSCESS; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DEHYDRATION; DIAPHYSIS DYSPLASIA; DIARRHEA; DRUG FEVER; FATIGUE; GASTROINTESTINAL PAIN; HUMAN; IMAGING SYSTEM; INFECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RECTAL PAIN; RECTUM CANCER; REVIEW; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 77953631538     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181e0761c     Document Type: Review

References (103)

1. National Institutes of Health Consensus Conference: adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444.
2. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-715.
3. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med. 2005;352:2696-2704.
4. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med. 2004;350:2343-2351.
5. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456-3461.
6. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2009;27:abstract LBA4.
7. Sargent D, Yothers G, van Cutsem E, et al. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: new data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSABP C-06 and C-07, and C89803. J Clin Oncol. 2009;27:abstract 4011.
8. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control - final report of Intergroup 0114. J Clin Oncol. 2002;20:1744-1750.
9. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup trial 0114. J Clin Oncol. 2004;22: 648-657.
10. Meyerhardt JA, Tepper JE, Neidzwiecki D, et al. Impact of hospital procedure volume on surgical operation and long-term outcomes in high risk curatively resected rectal cancer: findings from the Intergroup 0114 study. J Clin Oncol. 2004;22:166-174.
11. Roh MS, Colangelo LH, O'Connell MJ, et al. Pre-operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum (NSABP-R-03). J Clin Oncol. 2009;27:5124-5130.
12. Sauer R, Becker H, Hohenberger P, et al. Preoperative chemoradiotherapy as compared with postoperative chemoradiotherapy for locally advanced rectal cancer. New Engl J Med. 2004;351:11.
13. Fietkau R, Rodel C, Hohenberger W, et al. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys. 2007;67:1008-1019.
14. Salerno GV, Daniels IR, Moran BJ, et al. Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum. 2009;52:632-639.
15. Mercury Study Group: diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779.
16. Bail SH, Kim NK, Lee YC, et al. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol. 2007;14:462-469.
17. Barbaro B, Valentini V, Coco C, et al. Tumor vascularity evaluated by transrectal color doppler US in predicting therapy outcome for low-lying rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1304-1308.
18. Valentini V, DePaoli A, Gambacorta MA, et al. Chemoradiation with infusional 5-FU and ZD1839 (Gefitinib-Iressa) in patients with locally advanced rectal cancer: a phase II trial. Int J Radiat Oncol Biol Phys. 2006;66:s168.
19. Kim NK, Kim MJ, Park JK, et al. Preoperative staging of rectal cancer with MRI: accuracy and clinical usefulness. Ann Surg Oncol. 2000;7:732-737.
20. Nahas CSR, Akhurst T, Yeung H, et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol. 2008;15:704-711.
21. Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histolopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum. 2008;51:21-25.
22. Kalff V, Ware R, Heriot A, et al. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys. 2009;74:60-66.
23. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641-1648.
24. Harisinghani MG, Barentsz J, Hahn PF. Noninvasive detection of clinically occult lymph-node metastasis in prostate cancer. N Engl J Med. 2003;348: 2491-2499.
25. Shami VM, Parmer KS, Waxman I. Clinical impact of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration in the management of rectal carcinoma. Dis Colon Rectum. 2004;47:59-65.
26. Kim YH, Kim DY, Kim TH, et al. Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:761-768.
27. Kuo LJ, Chern MC, Tsou MH, et al. Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum. 2005;48:23-28.
28. Barbaro B, Schulsinger A, Valentini V, et al. The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 1999;43:1043-1047.
29. Guillem JG, Chessin DB, Shia J, et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate endpoint. J Clin Oncol. 2005;23:3475-3479.
30. Barbaro B, Fiorucci C, Tebala C, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology. 2009;250:730-739.
31. Calvo FA, Domper M, Matute R, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58:528-535.
32. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15-24.
33. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215-1223.
34. Bosset JF, Collette L, Bardet E, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med. 2006;355:1114-1123.
35. Gerard JP, Conroy T, Bonnetain F. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;28:4620-4625.
36. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379-4386.
37. Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference. Radiother Oncol. 2009;92:148-163.
38. Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated with surgery alone. J Clin Oncol. 2006;24:4078-4084.
39. Green FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging system for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004;22:1778-1784.
40. Kim JH, Beets GL, Kim MJ, et al. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol. 2004;52:78-83.
41. Roedel C, Fietkau R, Raab R, et al. Tumor regression grading as a prognostic factor in patients with locally advanced rectal cancer treated with preoperative radiochemotherapy. Int J Radiat Oncol Biol Phys. 2004;60: s140.
42. Read TE, Andujar JE, Caushaj FP, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum. 2004;47:825-831.
43. Vecchio FM, Valentini V, Minsky B, et al. The relationship of pathologic tumor regression grade (trg) and outcome after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752-760.
44. Guillem JG, Diaz-Gonzalez J, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol. 2008;26:368-373.
45. Mendenhall WM, Bland KI, Rout WR, et al. Clinically resectable adeno- carcinoma of the rectum treated with preoperative irradiation and surgery. Dis Colon Rectum. 1988;31:287-290.
46. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303-312.
47. Nagtegaal ID, van de Velde CJH, Marijnen CAM, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23:9257-9264.
48. Guillem JG, Chessin DB, Shia J, et al. A prospective pathologic analysis using whole mount sections of rectal cancer following preoperative combined modality therapy. Implications for sphincter preservation. Ann Surg. 2007;245:88-93.
49. Branagan G, Chave H, Fuller C, et al. Can magnetic resonance imaging predict circumferential margins and TNM stage in rectal cancer? Dis Colon Rectum. 2004;47:1317-1322.
50. Burton S, Brown G, Daniels I, et al. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:445-451.
51. Rutten H, Sebag-Montefiore D, Glynne-Jones R, et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol. 2006;24:3528.
52. Sebag-Montefiore D, Steele R, Quirke P, et al. Routine short course pre-operative radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. J Clin Oncol. 2006;24:3511.
53. Marijnen CAM, Nagtegaal ID, Kapiteijn E, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:1311-1320.
54. Sauer R, Roedel C. The author's reply. New Engl J Med. 2005;352:510.
55. Habr-Gama A, de Souza, PM, Ribeiro U, et al. Low rectal cancer. Impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41:1087-1096.
56. Gavioli M, Bagni A, Piccagli I, et al. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer. Dis Colon Rectum. 2000; 43:1075-1083.
57. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131-135; discussion 135-136.
58. Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose- positron emission tomography assessment of response to preoperative chemoradiation: a means for determining long term outcomes of rectal cancer. J Am Coll Surg. 2004;199:1-7.
59. Heriot AG, Hicks RJ, Drummond EGP, et al. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum. 2004;47:451-458.
60. Dzik-Jurask A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet. 2002;360:307-308.
61. Glynne-Jones R, Wallace M, Livingstone JI, et al. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum. 2008;51:10 -19; discussion 19-20.
62. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU) based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adjuvante Retto (STAR)-01 randomized phase III trial. 2009 GastrointestinalCancers Symposium. San Francisco, CA; January 15-17, 2009
63. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients with locally advanced rectal cancer (LARC): results of the ACCORD 12/0405 PRODIGE 2. J Clin Oncol. 2009;27:abstract LBA4007.
64. Willett CG, Duda D, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-3026.
65. van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTA experience. J Clin Oncol. 2009;27:abstract 2.
66. Lordick F, Geinitz H, Theisen J, et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006;64:1295-1298.
67. Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006;66:1378-1383.
68. Chung KY, Minsky B, Schrag D, et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol. 2009;27:abstract 3560.
69. Rodel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1081-1086.
70. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging defined poor risk rectal cancer. J Clin Oncol. 2006;24:668-674.
71. Fernandez-Martos C, Aparicio J, Salud A, et al. Multicenter randomized phase II study of chemoradiation (CRT) followed by surgery (S) and chemotherapy (CT) versus induction chemotherapy followed by CRT and S in high-risk rectal cancer: GCR-3 final efficacy and safety results. J Clin Oncol. 2009;27:abstract 4087.
72. Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum. 2003;46:448-453.
73. Valentini V, Coco C, Picciocchi A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002;53:664-674.
74. Guillem JG, Chessin DB, Cohen AM, et al. Long term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-836; discussion 836-838.
75. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72:99-107.
76. Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and post treatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1455-1461.
77. Unsal D, Under A, Akyuerk N, et al. Matrix Metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:196-203.
78. Johnston PG. Prognostic markers of local relapse in rectal cancer: are we any further forward? J Clin Oncol. 2006;24:4049-4050.
79. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74:673-688.
80. Konski A, Li T, Sigurdson E, et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009;74:55-59.
81. Borschitz T, Wachtlin D, Mohler M, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol. 2008;15:712-720.
82. Koelbl O, Vordermark D, Flentje M. The relationship between belly board position and patient anatomy and its influence on dose-volume histogram of small bowel for postoperative radiotherapy of rectal cancer. Radiother Oncol. 2003;67:345-349.
83. Roels S, Duthoy W, Haustermans K, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1129-1142.
84. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824-830.
85. Meyer J, Czito B, Yin FF, et al. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorec Cancer. 2007;6:348-356.
86. Aristu JJ, Arbea L, Rodriguez J, et al. Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71:748-755.
87. Tatsuzaki H, Urie MM, Willett CG. 3-D comparative study of proton vs. x-ray radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 1991;22:369-374.
88. Callister MD, Ezzell GA, Gunderson LL. IMRT reduces the dose to small bowel and other pelvic organs in the preoperative treatment of rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:290.
89. Withers HR, Peters LJ, Taylor JM. Dose-response relationship for radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys. 1995;31:353-359.
90. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group trial 0012. J Clin Oncol. 2006;24:650-655.
91. Fakih MG, Rajput A, Yang GY, et al. A phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006;65:1462-1470.
92. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol. 2005;23:1350-1357.
93. Allal A, Bieri S, Gervaz P, et al. Preoperative concomitant hyperfractionated radiotherapy and gemcitaibine for locally advanced rectal cancers: a phase I-II trial. Cancer J. 2005;11:133-139.
94. Krishnan S, Janjan NA, Hoff PM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:762-771.
95. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer. J Clin Oncol. 2008;26:abstract 4091.
96. Hospers GAP, Punt CJA, Tesselaar ME, et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer: A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol. 2007;14:2773-2779.
97. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol. 2005;16:1898-1905.
98. Avallone A, Delrio P, Guida C, et al. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. Br J Cancer. 2006;94:1809-1815.
99. Ryan DP, Niedzwiecki D, Hollis D, et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006;24:2557-2562.
100. Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with singleagent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73:466-472.
101. Navarro M, Dotor E, Rivera F, et al. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:201-205.
102. Valentini V, Coco C, Minsky BD, et al. Randomized multicenter phase IIB study of preoperative chemoradiotherapy in T3 mid-distal recta cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil +radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:403-412.
103. Wong SJ, Winter K, Meropol NJ, et al. RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. J Clin Oncol. 2008;26:abstract 4021.